Sign in

You're signed outSign in or to get full access.

EM

Envoy Medical, Inc. (COCH)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 was operationally positive but financially challenged: revenue fell to $46k as battery replacement sales declined due to supply chain constraints, while operating loss widened modestly on higher R&D tied to the pivotal trial .
  • EPS beat consensus: diluted EPS of -$0.29 vs S&P Global consensus of -$0.36, driven by fair value gains on warrant liabilities and lower G&A vs prior year; revenue missed consensus ($46k vs $65k)* .
  • Clinical execution accelerated: first-stage pivotal trial fully enrolled (10 participants), six activated, two completed 1-month follow-up; no serious adverse events or unanticipated adverse device effects reported .
  • Liquidity improved via insider funding: a $10M unsecured facility (initial $5M draw at 8% with interest deferred two years) supports trial velocity; however, Nasdaq issued a market value deficiency notice, creating potential listing risk .

What Went Well and What Went Wrong

What Went Well

  • Pivotal trial momentum: “Completed Enrollment of 10 participants in ‘first stage’… Activated (i.e., turned on) six of 10 participants… No reports of Serious Adverse Events or Unanticipated Adverse Device Effects.” .
  • Product positioning resonates: “We believe… a meaningful percentage of patients… will be drawn to a fully implanted solution that uses the ear to pick up sound… does not have an implanted magnet… and has multiple days of battery life.” — CEO Brent Lucas .
  • Balance of costs: YoY G&A decreased by $284k, partially offsetting R&D increases; management controlled certain legal/professional fees vs prior year .

What Went Wrong

  • Revenue headwinds: Net revenues declined $13k YoY as battery replacement sales fell on supply chain limitations; COGS rose $73k on headcount and supplier expenses .
  • Cash burn continues: Net cash used in operations was -$3.73M in Q1 as trial and scaling costs rose, requiring external financing to sustain execution .
  • Listing risk: Nasdaq market value deficiency notice (Rule 5550(b)(2)); COCH must exceed $35M market value for 10 consecutive business days by Aug 25, 2025 to regain compliance .

Financial Results

Revenue and EPS (Oldest → Newest)

MetricQ3 2024Q4 2024Q1 2025
Revenue ($USD Thousands)56 42*46
Diluted EPS ($USD)-0.37 -0.48*-0.29

Values with an asterisk are retrieved from S&P Global.

Operating Results and Expenses (Oldest → Newest)

MetricQ3 2024Q4 2024Q1 2025
Operating Loss ($USD Thousands)(4,974) (4,524)*(5,107)
Total Operating Expenses ($USD Thousands)5,030 4,566*5,153
R&D Expenses ($USD Thousands)2,757 2,485*2,748
Sales & Marketing ($USD Thousands)394 361*358
General & Administrative ($USD Thousands)1,692 2,068*1,821

Values with an asterisk are retrieved from S&P Global.

Cash and Cash Flow

MetricQ3 2024Q4 2024Q1 2025
Cash and Equivalents ($USD Thousands)4,424 5,483 5,312
Cash from Operations ($USD Thousands)(2,623)*(4,388)*(3,725)

Values with an asterisk are retrieved from S&P Global.

Estimates vs Actual (Q1 2025)

MetricActualConsensusSurprise
Revenue ($USD Thousands)46 65*Miss: -$19k
Diluted EPS ($USD)-0.29 -0.36*Beat: +$0.07

Values with an asterisk are retrieved from S&P Global. EPS and Revenue consensus each based on 4 estimates*.

KPIs (Clinical Progress)

KPIQ3 2024Q4 2024Q1 2025
Pivotal CI Enrollment (Stage 1)FDA approval to initiate pivotal trial 6 enrolled/implanted; 2 activated 10 enrolled; 6 activated; 4 scheduled in May
Follow-up——2 completed 1-month follow-up
Safety—Early Feasibility: no UADE/SADE at 24 months No SAEs or UADEs reported
Reimbursement/CodesAMA CPT codes for totally implantable middle ear devices approved Reinforced CPT; pushing Hearing Device Coverage Clarification Act Continued advocacy; update on Esteem program

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Company GuidanceFY/Q1 2025None providedNone providedMaintained: No formal financial guidance

Earnings Call Themes & Trends

No Q1 2025 earnings call transcript was available in the document set; themes are derived from press releases and filings.

TopicPrevious Mentions (Q3 2024)Previous Mentions (Q4 2024)Current Period (Q1 2025)Trend
Pivotal CI Trial ExecutionFDA approval to initiate pivotal trial 6 enrolled/implanted; 2 activated Stage-1 fully enrolled (10), 6 activated, 2 completed 1-month Improving
Safety Profile—Early Feasibility: no UADE/SADE at 24 months No SAEs or UADEs reported in pivotal stage Stable/Positive
Reimbursement (Esteem FI-AMEI)AMA Category III CPT approved Continued advocacy; Medicare coverage bill progress Ongoing engagement; patient programs added Improving
Supply ChainBattery replacement constraints impacting revenue Continued constraints Ongoing constraints; revenue impact Persistent Headwind
Funding/Liquidity—Year-end cash $5.5M New $10M facility (initial $5M draw) Improving Liquidity
Listing StatusRussell Microcap inclusion —Nasdaq MVLS deficiency notice Deteriorating Listing Risk

Management Commentary

  • “We could not be more pleased with the positive progress of our pivotal clinical study and the reported excitement from the investigational sites… we believe… a meaningful percentage of patients… will be drawn to a fully implanted solution…” — Brent Lucas, CEO .
  • “We are very happy with the enrollment progress in the first stage of our pivotal clinical trial… We believe that interest will only grow as awareness is increased and further progress is made.” — March 12 funding release .
  • Cost discipline: G&A down YoY by $284k; S&M up modestly to support patient engagement programs .

Q&A Highlights

  • No Q1 2025 earnings call transcript was available; therefore, no Q&A highlights, clarifications, or tone assessment can be provided from a call in this period.

Estimates Context

  • EPS beat: -$0.29 actual vs -$0.36 S&P Global consensus; driven by $615k combined warrant liability fair value gains offsetting higher interest expense and R&D, plus lower YoY G&A *.
  • Revenue miss: $46k actual vs $65k consensus; management cited battery replacement sales decline due to supply chain limitations *.
  • Coverage depth: 4 estimates for both EPS and revenue in Q1 2025*.

Values retrieved from S&P Global.

Key Takeaways for Investors

  • Clinical de-risking continues: full enrollment, activations progressing, and no SAEs reported — supports medium-term thesis on Acclaim CI’s safety/performance profile .
  • Near-term revenue is not a driver; watch operational milestones (activations, follow-ups, pivotal data cadence) and reimbursement steps for Esteem FI-AMEI .
  • Liquidity runway extended via insider financing (deferred interest, unsecured, no conversion), reducing financing overhang near-term; monitor draw cadence and cash burn trajectory .
  • Estimate revisions: likely modest upward EPS adjustments given the beat and lower G&A YoY, but revenue likely revised down near-term due to persistent supply chain constraints *.
  • Listing risk is a potential stock overhang through Aug 25, 2025; catalysts to regain compliance include trial updates, strategic funding, or market cap actions .
  • Watch for additional regulatory and coding developments (CPT utilization, Medicare classification) that could unlock Esteem reimbursement and diversify revenue .
  • Trading lens: headline catalysts include pivotal trial milestones and any reimbursement wins; funding and listing status updates may drive near-term volatility .

Values with an asterisk are retrieved from S&P Global.